Preliminary market consultations (PMC)

The recent LCSP (Public Sector Contracts Law), Law 9/2017, transposing the new classic Contract Directive, incorporates the regulation of preliminary market consultations in Article 115, which in practice involves a procedure that has as its purpose obtain information on market capacity, the state of science or technology and inform economic operators about the projects and requirements for future hiring.

Thus, the contracting authorities through this procedure, may request or accept the advice of experts or independent authorities or market participants, which may be used in the planning and development of the procurement procedure, provided that such advice does not have the effect of distorting competition and does not result in violations of the principles of non-discrimination and transparency.

As a preliminary step to the definition of public procurement models of innovation that will be developed in the Applied Personalized Medicine Project-MedeA, it is considered of interest to promote a procedure of preliminary market consultations as an open call for proposals for innovative solutions, as a means to identify technologies and solutions of interest for the technological challenges proposed in the MedeA project.

The purpose of this call is to promote the participation of any person, physical or legal, public or private for the identification of innovative proposals that will contribute to the process of development and execution of the bids and / or lots included in the Project Applied Personalized Medicine-MedeA , in the strategic lines of Health Care and Clinical Trials defined in the project.
The present process of preliminary market consultations is carried out with a view to preparing future contracts that the Extremadura Health Service (SES) plans to develop during 2019, and inform economic operators about their plans and their contracting requirements.

In any case, the provisions of section 2 of article 115 of the LCSP shall apply, “[…] The consultations carried out may not result in a specific and delimited contractual object that only meets the technical characteristics of one of the consulted. The results of the studies and consultations should, where appropriate, be specified in the introduction of generic characteristics, general requirements or abstract formulas that ensure a better satisfaction of public interests, without, in any case, the consultations carried out carrying advantages of the award of the contract for the participating companies in those. “

The call is open and is addressed to all physical or legal persons, public or private, who have R & D & I capabilities and production of products and services that can be exploited in the market, who have the will to participate and collaborate with the Service. Extremeño de Salud (SES) for the development of said project, both in its definition and scope and in the development and technological innovation in the strategic lines defined in the project. The participation in the call does not involve the Extremadura Health Service (SES) or the Autonomous Administration any obligation to finance or accept the proposals submitted.

The SES will give participants equal and non-discriminatory treatment, and will adjust their participation to the principle of transparency.
Likewise, the SES will comply with the provisions of section 3 of Article 115 of the LCSP “[…] In no case during the consultation process referred to in this article, the contracting body may disclose the participants in it the solutions proposed by the other participants, being the same only known in their entirety. “

The SES, as contracting entity, may disclose the solutions presented by the economic operators, although it may not disclose the technical or commercial information that, if applicable, has been provided by the participants and which they have designated as confidential.
Participants will be the ones who must identify the documentation or technical or commercial information that they consider to be confidential, not being admissible to make a generic declaration or declare that all documents or all information is confidential.

Participants may designate any of the documents provided in their application as confidential. This circumstance must be clearly reflected (in any way, or on the margin) in the document designated as such.

The contracting body will store the contact details of the participants in the procedure. These data will necessarily be included in the proposals presented by the participants, which will also include their express consent and acceptance of the conditions established in the present procedure, including the possibility that the contracting authority may disseminate their participation and solutions presented in the procedure, if relevant, that will be included in the mandatory report of the actions carried out, in accordance with section 3 of Article 115.


Budget: 3.827.265 Euros 

Dedline for proposals: 30 may, 2019

 Annoncement: English: (DOC02CPM02_english)

Official publication: b591f9061a7290d5/DOC20190226093428Anuncio+Consulta+Previa+Mercado++MEDEA.pdf?MOD=AJPERES

Publlc Meet the Market Event: To be annonced (probably april)

Proposals: This web page

Consultations: This web page

Form / Proposal sheet for innovative solutions

TECHNOLOGICAL DEMAND 01: “Personalized Drug Prescription System” – PPS

Develop an electronic prescription module that allows the personalized selection of the most appropriate active ingredient in each situation. Integrated in the Electronic Clinical History, specifically in the JARA (SES).

TECHNOLOGICAL DEMAND 02: Molecular Laboratory “Molecular analysis of pharmacogenetic biomarkers”

Develop a systematic analysis of pharmacogenetic biomarkers for its implementation in the clinical routine, validated to include all relevant variants for the population of Extremadura, Spain and as far as possible European.

DEMAND TECNOLÓGICA 03: Pharmacological and Analytical Laboratory “Chemical-pharmaceutical and other relevant analysis”

Develop a systematic analysis of plasma levels of drugs and metabolites, validated, which includes the most commonly prescribed drugs, or those in which there is recommendation in the determination of levels or Serious Adverse Reactions.

TECHNOLOGICAL DEMAND 04: Analysis in clinical units and of Clinical Trials “Evaluation and Implementation in Clinical and Care Assay Units”

Carry out an evaluation of the clinical impact, but above all economic, and of the use of health systems in the clinical context and of clinical research, mainly patients involved in Clinical Trials in order to design implementation strategies.

TECHNOLOGICAL DEMAND 05: Tools for clinical evaluation and adverse reactions “Use of biosensors and other procedures to perform the evaluation of efficacy and adverse reactions in real life”

Develop tools for evaluation of response and adverse reactions in real life.